Business

Know the Business

Convatec is a recurring-revenue chronic-care consumables compounder dressed as "medical devices" — patients on its products do not stop using them, and >90% of revenue is repeat orders for pouches, dressings, catheters, and infusion sets. The economic asset is the installed patient base plus a small number of reimbursement gatekeepers; the right comparable is Coloplast, not Smith+Nephew or Becton Dickinson. The market mainly underestimates the recurring-revenue durability and the path from 22.3% to mid-20s adjusted op margin, and overestimates the lasting damage from one-off CMS rulings (skin-substitute reset, DMEPOS competitive bidding) that reset 1–2% of revenue but rarely change the long-run engine.

1. How This Business Actually Works

The engine is simple: every day, more than a million patients open a sealed pouch, dressing, catheter, or infusion set with Convatec's name on it, and a payer (Medicare, an EU public system, an insurer) reimburses a code-based price per piece. The company sells over 1 billion units a year across four franchises, manufactured in 7 plants on automated lines and pushed through hospital GPO contracts and captive home-delivery (180 Medical, Amcare). Once a patient is fitted, switching is medical, not financial — that is why the asset is patient-stickiness, not technology.

The four franchises share scale (polymer/adhesive science, automated sterile manufacturing, regulatory compliance, GPO selling) but face different competitive arenas and reimbursement clocks. Infusion Care is the outlier — it grows with the durable-pump installed base (Tandem, Beta Bionics, Medtronic) and a separate subcutaneous-biologics curve (AbbVie's Parkinson's therapy Vyalev), at double the rate of the other three.

The economic flywheel: small absolute prices keep payers tolerant; high recurrence keeps revenue compounding; manufacturing scale plus regulatory burden keep new entrants out; commercial productivity (SG&A from ~40% in 2021 to ~36% now) is where incremental margin is being mined. Profit dollars are made in the SG&A line, not the gross line — gross margin is already mature, the operating-margin gap to Coloplast is purely commercial productivity.

2. The Playing Field

Convatec sits in a strange spot: one of only two listed pure-play chronic-care consumables companies in the world (with Coloplast), competing against mega-cap diversified med-tech (BDX, SNN, SOLV) on three franchises and a true substitute (Insulet) on one. Coloplast is the benchmark — same business model, larger scale, ~6 percentage points more operating margin, and roughly 3× the equity value. That gap is the entire bull case.

What the peer set actually reveals: (1) the margin spread is not category-driven — Coloplast at 28% and ICU Medical at 8% are in adjacent categories; it is commercial productivity, channel ownership, and pure-play focus that drive the spread; (2) Convatec's 5% growth is understated — ex-InnovaMatrix it is 6.4% and Infusion Care is running 12.5%; (3) the listed peer table flatters consolidation — two of the three biggest competitors (Hollister and Mölnlycke) are private and sit between Convatec and Coloplast in scale, so the real industry is more concentrated than this table shows.

3. Is This Business Cyclical?

Demand is not cyclical — it is demographic. Convatec's revenue grew through 2008–09, 2020 (COVID), and the 2022–23 inflation pulse without breaking trend, because patients with chronic conditions cannot pause their consumption. The cycle that exists is regulatory: a CMS price code or coverage decision can move group revenue 1–2% in a single ruling, faster and harder than any GDP downturn would.

The two flat patches (2014–16 and 2019) were operational/strategic missteps, not demand cycles — pre-IPO restructuring under Nordic Capital, then a 2018–19 governance/operations crisis that triggered a profit warning. Both predated the FISBE turnaround. Volume growth itself never turned negative through any external shock.

4. The Metrics That Actually Matter

Generic ratios mislead here. The reported P/E spikes when one-off impairments hit (FY25 reported EPS 8.6¢ vs adjusted 17.6¢ because of the $72m InnovaMatrix charge); EBITDA margin looks ordinary because chronic-care players carry expensive nurse-education infrastructure; ROCE looks low because home-services M&A (180 Medical, Amcare) sits on the balance sheet at goodwill (35.7% of assets). These five metrics explain the actual quality of the business.

Margin progress is the single line a young analyst should track. Every 100 bps is roughly $24m of operating profit and ~3¢ of EPS at current revenue. The path from 22.3% to 25% is worth ~$65m of operating profit, before any revenue growth — that is the bulk of the reinvestment-runway thesis.

What gets missed if you only watch P/E and EV/EBITDA: (1) the FY25 reported P/E of 38× is not informative — it is a one-off impairment artefact; the adjusted figure is closer to 19×; (2) the FCF yield is reported above 5% but distorted by working-capital and capex timing — equity cash conversion on a comparable basis was 61% in FY25, an outflow into growth investment, not a deterioration of underlying quality.

5. What Is This Business Worth?

Convatec is best valued as one economic engine with a reinvestment runway, not a sum-of-the-parts. The four franchises share manufacturing, channel, R&D and reimbursement know-how; Convatec management runs them as one operating system (the FISBE strategy), and they would not be more valuable broken up. The right lens is normalised earnings power × multiple, where the work is in (a) deciding what normalised margin to credit and (b) deciding what multiple a mid-cap pure-play deserves vs Coloplast.

The valuation logic in one sentence: Convatec trades at roughly 14.5× EV/EBITDA, halfway between the diversified comparators (~11×) and the pure-play benchmark Coloplast (~22×). Closing half of the remaining gap to Coloplast (to ~18×) on a flat-EBITDA basis is roughly +25% equity value before any margin or growth contribution. The market is paying for "in transition," not "succeeded."

What would make the stock cheap or expensive from here:

• Cheap if: organic growth ex-InnovaMatrix sustains 6–8%, FY27 margin lands at 25%, and FY26 reimbursement events come through within guidance — the stock should re-rate toward 17–18× EV/EBITDA.
• Expensive if: any of three things break — DMEPOS CBP loses scope or excludes incumbents, FDA Warning Letter escalates to a consent decree on Infusion Care, or Coloplast/SOLV close the technology gap on insulin-pump infusion sets and erode IC pricing.

A sum-of-the-parts is not the right lens here. The franchises share too much (R&D, plants, channel, GPOs) for separate multiples to be defensible, and there is no listed subsidiary or stake to separately mark. SOTP would only become useful if management announced a divestiture (e.g., spinning Infusion Care to capture pump-OEM optionality) — which is not on the table.

6. What I'd Tell a Young Analyst

Watch four things, in this order. First, organic revenue growth ex-InnovaMatrix and constant-currency — every other metric is downstream of this number; if it lives in the 6–8% target, the FY27 acceleration thesis is intact. Second, the adjusted operating margin walk — each 100 bps is real; the path to mid-20s is the largest single driver of equity value. Third, the FDA dialogue on Unomedical — Infusion Care is the highest-growth franchise and the only one with a quality cloud over it; resolution removes the only acute downside risk; escalation to consent decree is the one event that reprices the stock. Fourth, the read-across from Coloplast and Smith+Nephew — they report 4–8 weeks ahead of Convatec on the same end-markets; their volume and pricing commentary is the best leading indicator of the quarter you are about to see.

The market is most likely underestimating two things: (i) how durable mid-single-digit volume growth actually is in chronic-care consumables once the patient is on the product, and (ii) how much commercial productivity remains to be mined in SG&A versus a Coloplast benchmark that has done it already. The market is most likely overestimating the durability of reimbursement shocks — the InnovaMatrix step-down is real but small (c.2% of group, fully called out, and operating leverage offsets most of it in FY26 on management's own guidance).

What changes the thesis: a second negative reimbursement event in 2026 that is not in the guide; a Warning Letter escalation; loss of a meaningful insulin-pump OEM contract (Tandem / Beta Bionics / Medtronic); or a margin year that goes sideways instead of up. None of those are base case — but they are the actual risks, and they are the right things to monitor. Everything else (FX, share price, sell-side ratings) is noise.